Загрузка...
A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
OBJECTIVE: Anlotinib, an oral small-molecular tyrosine kinase inhibitor (TKI) on tumor angiogenesis and growth, has a wide spectrum of inhibitory effects on targets such as vascular endothelial growth factor receptors 2/3 (VEGFR2/3), etc. The efficacy and safety of anlotinib in the treatment of plat...
Сохранить в:
| Опубликовано в: : | Drug Des Devel Ther |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7850384/ https://ncbi.nlm.nih.gov/pubmed/33536747 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S286529 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|